Business Wire

REPLY

22.11.2021 09:32:03 CET | Business Wire | Press release

Share
REPLY: Reply’s Hybrid Work Research Confirms that “Hybrid work is not a passing trend”, as it Focuses on the Rapid Evolution of Technologies Designed to Support the New Ways of Working

Increased productivity and advanced collaboration are only two of the benefits the new hybrid work models bring and will soon be the new normal in the business world. This is precisely the outcome from the new Hybrid Work research carried with Reply’s Trend SONAR, the proprietary trend detection and monitoring platform based on Artificial Intelligence - with the support of PAC (Teknowlogy Group).

The research estimated the main market trends using sector studies and evidence collected from Reply customers. Data from two different clusters of countries were then compared: the “Europe-5” (Italy, Germany, France, the Netherlands, Belgium) and the “Big-5” (USA, United Kingdom, Brazil, China, India). The aim was to understand the maturity of the market after the spent year and a half of pandemic life.

Companies that have accelerated their digital transformation during the pandemic define the hybrid work model as popular, effective and performing –the very reasons why there will be no turning back.

Aside from a few limitations related to remote collaboration, which technological innovation will increasingly be able to minimise, the new normal does not provide for a full-time return to physical workplaces as before, but rather for greater flexibility and hybrid work paradigms. This approach is expected to revolutionise office design, corporate culture and the overall employee experience. This scenario will benefit employees with better work-life balance and increase of work efficiency, as well as companies: smaller office spaces, flexible working hours, hiring of talent without the need for relocation.

As Filippo Rizzante, Reply CTO, mentions: “The digital world and technology have reshaped the future of the employee experience. Regardless of the specific working context, be it an office or a factory, hybrid work will increasingly be characterised by the support and collaboration of software or hardware based on artificial intelligence. This will be facilitated by greater data literacy and a propensity for digitisation which will not only be the prerogative of developers, but will instead play a key role for the entire workforce. The transition to remote and flexible working models will, to a certain extent, become a permanent fixture and the new corporate culture will have to welcome and embrace the digital dimension as an integral part of daily work routines, facilitating social connections and communication on site, as well as remotely. What’s more, themes such as sustainability and employee well-being will increasingly become an integral part of a company’s DNA.”

To enable the hybrid work scenario, information must be accessible in the cloud and seamless and instant collaboration must be made possible through the adoption of the right tools for each business and activity. At the infrastructure level, cloud computing is not just an option, it is becoming the standard that is driving hybrid architectures. Spending on public and private cloud technologies already represents more than half of the current global infrastructure spending and this is expected to reach two thirds by 2024.

This acceleration and migration is also fuelling investments in productivity tools that consist mostly of cloud-based and intelligent technologies. Reply’s study highlights that among the Europe-5 countries, this market is expected to reach €7.6 billion by 2025. The push towards cloud computing will also drive the market of the countries that make up the Big-5 cluster, which are expected to reach a market of €36 billion.

Another trend highlighted by Reply’s research is the growth of hyperautomation; another approach based on Artificial Intelligence which extends the use of automation to value-added activities. By 2025, nearly half of the largest global companies are expected to support workers with smart technologies designed to assist with complex interactions.

Cybersecurity is also one of the main enabling technologies for hybrid work, precisely because one of the greatest obstacles to this type of work is the potential vulnerability of corporate networks. For this very reason, security is one of the major investment areas in 2021 and it is not expected to be a short-lived trend. It is estimated that by 2025 the market for end-user device security, in other words security solutions for PCs, smartphones, tablets and other corporate devices, will grow by 45% among the Big-5 countries and by 34% among the Europe-5 countries.

A strong focus on sustainability accompanies the Hybrid Work model: Reply’s research shows that the workforce, and in particular the new generations, search for companies that operate with a solid purpose, that act in a responsible and sustainable manner from an environmental point of view and that have the courage to take a stand in social and cultural debates - with clear and measurable corporate ESG standards. The well-being of the workforce, mental health and quality of life are gaining more relevance in the hybrid work environment, alongside physical safety.

Hybrid work has become an essential factor in retaining talent and when facing the great resignation phenomenon, with almost half of under 35s who, according to global data, are considering quitting their jobs if forced to return to the office full time. As the business landscape continues to change, organisations need to improve their existing capabilities and provide access to distance learning platforms. It is estimated that the Big-5’s spending on online learning platforms will increase by 48% by 2025 , reaching €16 billion, while among the Europe-5s this value will reach €2 billion.

The full research can be downloaded here . This new research is part of the Reply Market Research series, which includes the research papers on “From Cloud to Edge” , “Industrial IoT: a reality check” e “Beyond Digital Marketing ”.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ReplyinUK/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye